Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Targeting replication stress recovery pathways in oncology (TENSION)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Netherlands
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-08-01
End date: 2021-07-31
Duration (months): 60.0
Total project cost (EUR): 1972500.0
EU funding (EUR): 1972500.0
Participants: 1
Project status: CLOSED

Genomic instability characterizes tumors, which have no clear ‘oncogenic-driver’ mutation, including triple-negative breast cancers (TNBCs). These patients do not benefit from molecularly targeted treatment and urgently need better treatment options. Increasing evidence points to replication stress as the driver of genomic instability. Since replication stress compromises cell viability, cells have evolved mechanisms to mitigate this threat. Recently, I discovered a novel cellular mechanism—mitotic Replication Stress Recovery (RSR)—that acts as an ‘emergency brake’ during mitosis, allowing recovery from high levels of replication stress. This machinery is critical for tumor cell survival, and therefore constitutes a promising target for anti-cancer drug development. However, it is unclear how this mitotic RSR is organized molecularly and how it can be targeted therapeutically. In this project, I aim to molecularly define and therapeutically target the Mitotic Replication Stress Recovery (RSR) machinery in triple-negative breast cancer cells. To this end, I will implement a series of complementary innovative strategies. First, I will use mass-spec-based proteomics to molecularly characterize components and wiring of the mitotic RSR machinery. Second, to identify the genetic profiles of cancer subgroups that are sensitive to inactivation of the mitotic RSR, functional genetic screens will be combined with visualization and quantification of replication stress in genomically-defined human cancer samples. Finally, my findings will be translated to the pre-clinical situation by exploring the feasibility of therapeutic inactivation of the RSR machinery in vitro and in vivo in a panel of triple-negative breast cancer models. In summary, TENSION will provide advanced insight into the composition and wiring of the mitotic RSR machinery and will reveal the potency of targeting this pathway therapeutically for TNBCs and other hard-to-treat, genomically instable cancers.

Keywords: breast cancer,mitosis,dna repair,genomic instability
Low price wave energy conversion through force cancellation. (Wavepiston)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Action type: SME instrument
Countries involved: Italy,Finland,Netherlands,Denmark
Call: Stimulating the innovation potential of SMEs for a low carbon energy system (H2020-SMEINST-1-2014, 2014)
Start date: 2015-02-01
End date: 2015-05-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 4
Project status: CLOSED

No attempt to harvest energy from waves has resulted in an economically viable and competitive technology. Many projects stopped and investors have become sceptical of wave power. Currently the cost per watt of usable wave energy is high, due to a focus on energy conversion methods and efficiency, rather than on mooring and grid connection, accounting for more than 90% expenditure. Wavepiston is a break through near-shore wave power technology producing energy from waves at a competitive price with respect to the most efficient renewable energy technologies. The system consists of identical modules mounted on a string pumping pressurized water to shore for successive energy conversion. Using Wavepiston’s patented “force cancellation” principle the system is able to reduce the amount of forces on the mooring and structure to 1:10, requiring a simpler structure and therefore reducing capital costs. The Wavepiston system can provide cost efficient, clean and reliable renewable energy to help meet Europe’s increasing demand and achieve emissions reduction targets. The offshore application ensures it is a suitable fit also for remote islands and isolated coastal communities. The Wavepiston system was conceived in 2006 and in 2009 the concept of force cancellation was patented. In 2010 numerous tank tests were performed with a system 1:30 the size, that experimentally validated the system and proved each panel can harvest more than 5% of the energy contained in a wave. In 2013 a proof of concept was carried out offshore with a system 1:9 the size and it worked better than predicted. Vryhof Anchors and Nurmi Cylinders, specialised in offshore mooring and hydraulic pumps respectively, have joined the project to support product industrialization. Phase 1 will assess various business models (with the support of the ESCO company EnerMed partner in the project), establish a complete supply chain and plan all activities for the large scale pilot to be held in Ireland.

Keywords: wave energy,energy efficiency,renewable energy technologies
Omics integration for precision cancer immunotherapy (IMMUNOMARK)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-03-01
End date: 2020-02-29
Duration (months): 24.0
Total project cost (EUR): 170121.6
EU funding (EUR): 170121.6
Participants: 1
Project status: CLOSED

The development of immunotherapies based on checkpoint inhibitors marks the beginning of a new era in the treatment of cancer, with 20-30% of tumor response in advanced non–small-cell lung cancer and melanoma. However, the rational use of these agents has been limited by the lack of definitive predictive biomarkers. The recent “omics revolution” provides great opportunities to elucidate the biological processes linked to the treatment outcome. Here we propose a multilayer integrative omics analysis using transcriptomics and genetic and epigenetic mapping, together with detection of specific immunologic proteins, to identify biomarkers of clinical response to immunotherapy amenable to be used in liquid biopsies. Objective: to identify definite biomarkers predictive of the response to anti-PD-1, anti-PD-L1, and anti-CTLA4 therapy in patients with metastatic melanoma and advanced non–small-cell lung cancer. We structure the proposal in two parts: WP1. Signature of response to the immunotherapy by integrating transcriptomics and genetic and epigenetic mapping in tumor tissues: solid biopsy. Genome-wide transcriptomics on FAC-sorted tumor and stroma cells followed by targeted genetic and epigenetic mapping in the differentially expressed genes in responders. WP2: Identification of circulating biomarkers of response to the immunotherapy: liquid biopsy. Pre- and post-treatment blood samples from a validation cohort will be used as liquid biopsy. Genetic and epigenetic biomarkers of WP1 will be tested as circulating biomarkers. In addition, LINE-1 methylation, total Circulating Tumor Cells, CD56+, or CD8+ PD-1+ cells will be tested. This project applies multiple innovative approaches to address the urgent need of identifying biomarkers of clinical response to immunotherapy in cancer, amenable to be used non-invasively. In line with the Horizon 2020 Research & Innovation goal, we will “improve our ability to monitor health and to prevent, detect, treat and manage disease.

Keywords: dna methylation and hydroxymethylation,pharmacoepigenetics,liquid biopsy,immune cells related,biomarkers,immune tolerance,anti pd1,anti pd l1,anti ctla4,tumor,stroma,omics integration
Ultrasound peripheral interface and in-vitro model of human somatosensory system and muscles for motor decoding and restoration of somatic sensations in amputees (SOMA)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Spain,Italy,Iceland,Germany,Italy,United Kingdom,United Kingdom
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2019)
Start date: 2020-09-01
End date: 2024-08-31
Duration (months): 48.0
Total project cost (EUR): 2999998.75
EU funding (EUR): 2999998.75
Participants: 7
Project status: SIGNED

The SOMA project tackles three grand challenges in the field of upper-limb neuroprosthetics: a) to develop a completely novel low invasive peripheral interface for restoring natural and multimodal tactile sensations in amputee subjects, with high selectivity and discrimination capabilities thanks to focused UltraSound (US) stimulation, b) to develop and validate an in-vitro model of the innervated natural skin and its sensory receptors, through the application of cutting edge tissue engineering technology and neurocomputational modelling, for the study of spatio-temporal relationships between cutaneous stimuli and afferent neural signals, and for the validation of stimulation techniques of the Peripheral Nervous System (PNS), c) to demonstrate the effectiveness of the newly developed interface through the closed-loop sensori-motor control of an upper-limb prosthesis.. The novel low invasive peripheral interface will rely on focused US probes, implantable wireless technologies and new encoding algorithms capable of generating multimodal sensations related to mechanoreceptors (for mechanical pressure), nociceptors (for pain) and thermoreceptors (for changes in temperature). The in-vitro model of the somatosensory system will be composed of a biohybrid fully innervated sensitive skin, which replicates in-vitro the complex cutaneous somatosensory system of the human skin. The project aims to experimentally validate the in-vitro model, to unravel the role of the sense of touch in both exteroception and proprioception and to provide as ultimate goal a test-bed useful to investigate and test new stimulation techniques. The development of the novel peripheral interface and the in-vitro model will be carried out in parallel through a comparative analysis with the most advanced state-of-the art stimulation techniques and an experimental validation with in-vivo tests on animal models. Finally, a clinical validation on one amputee subject will be carried out.

Keywords: peripheral bidirectional interfaces,neuroprosthetics,somatic sensations and sensorimotor control
Looking for Super-Massive Neutron Stars (LOVE-NEST)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: Norway
Call: ERC CONSOLIDATOR GRANTS (ERC-2020-COG, 2020)
Start date: 2021-12-01
End date: 2026-11-30
Duration (months): 60.0
Total project cost (EUR): 1997625.0
EU funding (EUR): 1997625.0
Participants: 1
Project status: SIGNED

The astrophysics field of compact binary millisecond pulsars is thriving. This growing class of rapidly spinning neutron stars – also known as "spiders"– constitutes the most promising place to find massive pulsars. Super-massive neutron stars, with a mass significantly higher than two Solar masses, cannot contain exotic particles. Finding such stars would have profound implications for nuclear physics. The maximum neutron star mass has also important consequences for the fate of supernovae and the gravitational wave signal from neutron star mergers. In addition, spiders offer a unique probe of the pulsar's innermost wind and a nearby site for particle acceleration. The past years have seen exciting discoveries in this field, in which I have been closely involved. As a result, a new way has opened up to study fundamental astrophysical phenomena from compact binary millisecond pulsars. The purpose of this project is to find the most massive neutron stars and to understand the interaction between accretion flows, pulsar winds and neutron star magnetospheres. LOVE-NEST will first uncover a hidden population of millisecond pulsars, with a targeted search of gamma-ray candidate sources. We will then measure accurately the masses of the heaviest pulsars, using a novel technique that we have recently established. We will also investigate nearby spiders as potential sources of cosmic rays and astrophysical neutrinos, placing unprecedented constraints on particle acceleration in relativistic pulsar wind shocks. LOVE-NEST will have a strong impact on gravitational wave astronomy, nuclear physics, astrophysics and astro-particle physics. As a leader in the field, and having developed a new method to measure pulsar masses, I am in an excellent position to achieve these ambitious goals.

Keywords: neutron stars,millisecond pulsars,accretion flows,compact binaries,relativistic shocks,ultradense matter,cosmic rays
A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide (OligoG) for cystic fibrosis (OligoGpivotalCF)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Norway,Norway,Denmark,United Kingdom,United Kingdom
Call: New therapies for rare diseases (H2020-SC1-2017-Two-Stage-RTD, 2017)
Start date: 2018-01-01
End date: 2022-12-31
Duration (months): 60.0
Total project cost (EUR): 12163748.75
EU funding (EUR): 6013748.75
Participants: 8
Project status: CLOSED

The objective of the current proposal is to advance the orphan drug OligoG CF-5/20 (OligoG) through a pivotal phase IIb clinical trial, to enable a new and improved therapeutic approach for the orphan disease cystic fibrosis by 2024. The study drug is an alginate oligosaccharide derived from seaweed. Several properties relevant to the treatment of CF have been demonstrated using in vitro and ex vivo model systems including release of stagnant mucus, disruption of bacterial biofilm and increased bacterial susceptibility to antibiotics. OligoG received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, for the treatment of cystic fibrosis. The planned clinical trial will include approx 200 CF patients from approx. 35 European sites in coordination with the European Clinical Trial Network. The final study design, selection criteria, procedures and endpoints will be based on results from a recently finalized phase II study and will follow scientific advice and protocol assistance sought at the European Medicines Agency (EMA). A set of clinical and exploratory endpoints will be defined to assess the various effects of OligoG, comprising lung function assessed by spirometry and Lung Clearance Index (LCI) measurements, infection status assessed by frequency of pulmonary exacerbations and non-culture-dependent microbiology, and patient reported outcomes assessed by questionnaires, including standardised CF questionnaires (CFQ-R). A successful trial will enable preparation of international applications for conditional marketing authorisation (cMAA) throughout Europe and a New Drug Application (NDA) in the US, for the treatment of cystic fibrosis lung disease. In accordance with the work programme, a successful project will thus imply a new and improved therapeutic approach within cystic fibrosis available for CF patients by 2024.

Keywords: cystic fibrosis,pivotal clinical trial,clinical development,mutation independent therapy
Integrated Climate Adaptation Service Tools for Improving Resilience Measure Efficiency (CLARITY)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Theme: Fighting and adapting to climate change
Action type: Innovation actions
Countries involved: Italy,Spain,Austria,Germany,Italy,Austria,Sweden,Sweden,Sweden
Call: Exploiting the added value of climate services (H2020-SC5-2016-TwoStage, 2016)
Start date: 2017-06-01
End date: 2020-08-31
Duration (months): 39.0
Total project cost (EUR): 5906273.71
EU funding (EUR): 4999998.75
Participants: 20
Project status: CLOSED

Urban areas and traffic infrastructure linking such areas are highly vulnerable to climate change. Smart use of existing climate intelligence can increase urban resilience and generate added value for businesses and society at large. Based on the results of FP7 climate change, future internet and crisis preparedness projects (SUDPLAN, ENVIROFI, CRISMA) with an average TRL of 4-5 and following an agile and user-centred design process, end-users, purveyors and providers of climate intelligence will co-create an integrated Climate Services Information System (CSIS) to integrate resilience into urban infrastructure. As a result, CLARITY will provide an operational eco-system of cloud based climate services to calculate and present the expected effects of CC-induced and -amplified hazards at the level of risk, vulnerability and impact functions. CLARITY will offer what-If decision support functions to investigate the effects of adaptation measures and risk reduction options in the specific project context, and allow the comparison of alternative strategies. Four demonstration cases will showcase CLARITY climate services in different climatic, regional, infrastructure and hazard contexts in Italy, Sweden, Austria and Spain; focusing on the planning and implementation of urban infrastructure development projects. CLARITY will provide the practical means to include the effects of CC hazards and possible adaptation and risk management strategies into planning and implementation of such projects, focusing on increasing CC resilience. Decision makers involved in these projects will be empowered to perform climate proof and adaptive planning of adaptation and risk reduction options.

Keywords: climate services information system csis,large infrastructure,urban areas,cloud services
Moments in Time in Immersive Virtual Environments (MoTIVE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Computer science and informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: Spain
Call: ERC Advanced Grant (ERC-2016-ADG, 2016)
Start date: 2018-01-01
End date: 2023-12-31
Duration (months): 72.0
Total project cost (EUR): 2199318.0
EU funding (EUR): 2199318.0
Participants: 1
Project status: SIGNED

This project investigates how virtual reality (VR) can be used to live through an historical event so that participants perceive themselves to be there (Place Illusion) and take the events that are happening as real (Plausibility). To provide an application focus the research will be constructed around recreating a famous rock concert from the 1980s. The specific elements of the research involve an Agent Based Model (ABM) that populates the environment with thousands of virtual characters with their behaviour driven by the music. This ABM will run in VR embedding participants as a type of agent. Agents will have personality and emotional state that can influence one another, and the actions and state of participants will also influence the unfolding of the model. Based on the predictive coding model of brain functioning a theory of Place Illusion will be developed that results in a universal measurement. Similarly, the Plausibility Illusion will be modelled and corresponding universal measure derived. Participants in VR will be embodied, so that they will have a first person perspective life-sized virtual body that moves as they do. We will exploit the concept of body ownership and its consequences for attitudinal, behavioural, cognitive and agency changes to give people unique experiences of the virtual events, and carry out a series of experiments to assess the influence of being transported back in time in a younger body has on ageing. Our recent discovery that illusory agency can be realised through virtual embodiment will be used for research on improved motor learning. To allow people to move through the environment we will investigate paradigms for virtual walking, and in particular whether the multisensory principles involved in body ownership illusions can be used to lessen simulator sickness. The long term goal of the project is to understand how to capture treasured past moments lost in time, through their reproduction in ABM inspired virtual reality.

Keywords: virtual reality,virtual environments,presence,embodiment,immersion,body ownership,agency,agent based models
Sustainable managment of agriculture sources for development of climate-smart agricultural practices (AgPro4CSA)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Denmark,Canada
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-12-01
End date: 2025-09-28
Duration (months): 36.0
Total project cost (EUR): 273687.36
EU funding (EUR): 273687.36
Participants: 2
Project status: SIGNED

Unsustainable agricultural practices such as long-term monoculture of annual crops with the excessive use of mineral fertilisers lead to greenhouse gas emissions, and is threatening the sustainability of agricultural systems. The implication of poor soil quality on long-term agricultural production is of EU and global concern because of the increase in food and water demands. Diversification of agricultural systems and recycling of crop residues are important for the development of sustainable agroecosystems to cope with the challenges of food security, climate change mitigation and adaptation. The potential use of crop residues as an energy source is generating a debate in EU on sustainable utilisation of this resource in agriculture and bioenergy sectors, to gain the environmental suitability and for convenience of their large-scale exploitation. AgPro4CSA aims to develop improved agricultural management practices for increasing recycling of crop residues and reducing mineral fertilisers to reduce gaseous emissions and improve sustainability of crop production, which will promote environment friendly uses of crop residues in the agriculture and the energy sector, and will contribute in bio-based and circular economy. AgPro4CSA will cover fundamental understanding of mechanisms at the molecular, microbial and chemical levels, involved in nutrient cycling and GHG emissions in agricultural systems. Further, validation and assessment of biogeochemical models will provide valuable information for policy makers and environmental agencies. My enthusiasm for sustainable agroecosystems and my interdisciplinary research experience give me confidence to develop the AgPro4CSA project. The experience, facilities and support of the host and partner, ensure the successful completion of the project, at a time at which this research is highly relevant to current societal and environmental needs, as well as for strengthening my career development.

Keywords: greenhouse gas emissions,nutrient cycling,crop rotations,soil changes,soil microbial processes,bioenergy,biobassed economy,climate change mitigation,sustainability